Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 30, 2007
JNCI Journal of the National Cancer Institute 2007 99(21):1565-1567; doi:10.1093/jnci/djm206
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/21/1565    most recent
djm206v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Szabo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szabo, E.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2007.

EDITORIALS

Proliferative Changes in Chemoprevention Trials: Learning From Secondary Endpoints

Eva Szabo

Correspondence to: Eva Szabo, MD, Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Room 2137, 6130 Executive Blvd, Bethesda, MD 20852 (e-mail: szaboe@mail.nih.gov).

The first 10% of the full text of this article appears below.

Despite the successful demonstration of cancer preventive efficacy exemplified by agents such as tamoxifen and raloxifene for breast cancer, development of chemopreventive agents remains a difficult and challenging endeavor (1,2). Among the more daunting of the challenges is the identification of effective agents in early-phase clinical trials, before the sizable investment of resources required for phase III studies has occurred. The demonstration of preliminary efficacy requires not only an effective agent that is delivered appropriately for long enough to be effective but also the use of informative endpoints that predict the true endpoint of decreased cancer incidence. Whereas cancer treatment trials use surrogates such as tumor shrinkage to identify promising agents in phase II trials, cancer prevention trials seek to forestall the occurrence of future events (e.g., cancer). The . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Proliferative Changes in the Bronchial Epithelium of Former Smokers Treated With Retinoids
Walter N. Hittelman, Diane D. Liu, Jonathan M. Kurie, Reuben Lotan, Jin Soo Lee, Fadlo Khuri, Heladio Ibarguen, Rodolfo C. Morice, Garrett Walsh, Jack A. Roth, John Minna, Jae Y. Ro, Anita Broxson, Waun Ki Hong, and J. Jack Lee
J Natl Cancer Inst 2007 99: 1603-1612. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 1561. [Extract] [Full Text] [PDF]

Vitamin A Derivative Associated with Reduced Growth in Some Lung Cells
Liz Savage and Andrea Widener
J Natl Cancer Inst 2007 99: 1561. [Extract] [Full Text] [PDF]